ArcticZymes Technologies
Market Cap
kr2.7b
Last Updated
2020/10/30 21:53 UTC
Data Sources
Company Financials
Executive Summary
ArcticZymes Technologies ASA develops, manufactures, and markets immunomodulating beta-glucans and recombinant enzymes in Norway, Europe, Asia, Australia, Africa, and the Americas. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with proven track record.
Share Price & News
How has ArcticZymes Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AZT's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
1.4%
AZT
-9.2%
NO Biotechs
-5.2%
NO Market
1 Year Return
1,262.2%
AZT
15.6%
NO Biotechs
-14.0%
NO Market
Return vs Industry: AZT exceeded the Norwegian Biotechs industry which returned 20.8% over the past year.
Return vs Market: AZT exceeded the Norwegian Market which returned -13.3% over the past year.
Shareholder returns
| AZT | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.4% | -9.2% | -5.2% |
| 30 Day | -8.0% | 5.6% | -5.0% |
| 90 Day | 35.9% | 16.5% | -1.8% |
| 1 Year | 1,262.2%1,262.2% | 15.6%15.6% | -11.0%-14.0% |
| 3 Year | 727.1%727.1% | 38.7%36.8% | -3.0%-13.9% |
| 5 Year | 384.2%384.2% | 40.2%36.0% | 33.6%6.9% |
Price Volatility Vs. Market
How volatile is ArcticZymes Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Declining Stock and Solid Fundamentals: Is The Market Wrong About ArcticZymes Technologies ASA (OB:AZT)?1 month ago | Simply Wall St
Is ArcticZymes Technologies ASA (OB:AZT) Popular Amongst Insiders?2 months ago | Simply Wall St
Does ArcticZymes Technologies's (OB:AZT) Statutory Profit Adequately Reflect Its Underlying Profit?Valuation
Is ArcticZymes Technologies undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AZT (NOK59.8) is trading below our estimate of fair value (NOK179.47)
Significantly Below Fair Value: AZT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AZT is poor value based on its PE Ratio (59.8x) compared to the XE Biotechs industry average (33.5x).
PE vs Market: AZT is poor value based on its PE Ratio (59.8x) compared to the Norwegian market (14.9x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AZT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AZT is overvalued based on its PB Ratio (31.2x) compared to the NO Biotechs industry average (3.3x).
Next Steps
Future Growth
How is ArcticZymes Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
19.6%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ArcticZymes Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Check out ArcticZymes Technologies's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
- ArcticZymes Technologies competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has ArcticZymes Technologies performed over the past 5 years?
42.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AZT has high quality earnings.
Growing Profit Margin: AZT became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: AZT has become profitable over the past 5 years, growing earnings by 42.3% per year.
Accelerating Growth: AZT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AZT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (15.2%).
Return on Equity
High ROE: AZT's Return on Equity (52.4%) is considered outstanding.
Next Steps
Financial Health
How is ArcticZymes Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: AZT's short term assets (NOK102.9M) exceed its short term liabilities (NOK10.3M).
Long Term Liabilities: AZT's short term assets (NOK102.9M) exceed its long term liabilities (NOK14.5M).
Debt to Equity History and Analysis
Debt Level: AZT is debt free.
Reducing Debt: AZT has not had any debt for past 5 years.
Debt Coverage: AZT has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: AZT has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is ArcticZymes Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AZT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AZT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AZT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AZT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AZT's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Jethro Holter (48 yo)
1
Tenure
kr1,487,000
Compensation
Dr. Jethro Holter has been Chief Executive Officer of ArcticZymes Technologies ASA (formerly known as Biotec Pharmacon ASA) since April 22, 2020. He was an Interim CEO at Biotec Pharmacon ASA since October ...
CEO Compensation Analysis
Compensation vs Market: Jethro's total compensation ($USD156.29K) is below average for companies of similar size in the Norwegian market ($USD439.53K).
Compensation vs Earnings: Jethro's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1yr | kr1.49m | 0.0012% NOK 31.7k | |
| Chief Financial Officer | 6yrs | kr1.33m | 0.053% NOK 1.4m | |
| Employee Representative Director & Director of Operations | 1.42yrs | no data | 0.042% NOK 1.1m | |
| Director of IP & Business Development | 16.08yrs | no data | no data | |
| Director of Marketing | 0.75yr | no data | no data |
1.0yrs
Average Tenure
48yo
Average Age
Experienced Management: AZT's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Employee Representative Director & Director of Operations | 1.42yrs | no data | 0.042% NOK 1.1m | |
| Chairperson | 2.42yrs | kr425.00k | no data | |
| Director | 1.42yrs | kr105.00k | 0.17% NOK 4.5m |
1.4yrs
Average Tenure
Experienced Board: AZT's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
ArcticZymes Technologies ASA's company bio, employee growth, exchange listings and data sources
Key Information
- Name: ArcticZymes Technologies ASA
- Ticker: AZT
- Exchange: OB
- Founded: 1990
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr2.707b
- Shares outstanding: 48.33m
- Website: https://arcticzymes.com
Number of Employees
Location
- ArcticZymes Technologies ASA
- Sykehusveien 23
- PO Box 6463
- Tromsø
- Troms
- 9294
- Norway
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AZT | OB (Oslo Bors) | Yes | Ordinary Shares | NO | NOK | Nov 2005 |
| B4V | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Nov 2005 |
| 0DRV | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | NOK | Nov 2005 |
| AZTO | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | NOK | Nov 2005 |
Biography
ArcticZymes Technologies ASA develops, manufactures, and markets immunomodulating beta-glucans and recombinant enzymes in Norway, Europe, Asia, Australia, Africa, and the Americas. It operates through two ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/30 21:53 |
| End of Day Share Price | 2020/10/30 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.